| MCTC Stock | | | ILA 72.00 1.50 2.13% |
Director
Mr. Doron Debbie was appointed Independent Director at Micromedic Technologies Ltd effective May 2, 2019. His work experience includes the following roles Owner and Chief Executive Officer of Sigma Health Care, Founder and CoChief Executive Officer of MAC VC, External Director at Israel Post, Partner and Director at Avgady Group and Director at Capital Nature and Terrogence. He holds a BS degree in Industrial Engineering and Management Sciences from Ben Gurion University, a MBA degree, majoring in Finance and Marketing, from Tel Aviv University and a has attended an International MBA course at INSEAD, France. since 2019.
| Age | 57 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 972 73 2753450 |
| Web | http://www.m-medic.com |
Nextage Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. Nextage Therapeutics (MCTC) is traded on Tel Aviv Stock Exchange in Israel and employs 6 people.
Management Performance
Nextage Therapeutics Leadership Team
Elected by the shareholders, the Nextage Therapeutics' board of directors comprises two types of representatives: Nextage Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nextage. The board's role is to monitor Nextage Therapeutics' management team and ensure that shareholders' interests are well served. Nextage Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nextage Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Nextage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nextage Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.